Genedx Holdings Corp. - Class A (WGS) closed at $56.15 on October 23, 2026, down 16.4% from the previous close, on volume of 2,411,178 shares (30-day average 751,709).
Data as of October 23, 2026.
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
Business Wire (Fri, 23-Oct 4:05 PM ET)
Business Wire (Tue, 20-Oct 8:30 AM ET)
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Business Wire (Mon, 19-Oct 4:05 PM ET)
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
Business Wire (Wed, 7-Oct 8:30 AM ET)
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Business Wire (Fri, 2-Oct 8:30 AM ET)
Business Wire (Wed, 9-Sep 8:30 AM ET)
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Business Wire (Tue, 1-Sep 6:55 AM ET)
Business Wire (Mon, 24-Aug 8:30 AM ET)
Business Wire (Tue, 11-Aug 8:30 AM ET)
GeneDx to Participate in Upcoming Investor Conferences
Business Wire (Thu, 6-Aug 4:05 PM ET)
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Genedx Holdings Corp. - Class A trades on the NASDAQ stock market under the symbol WGS.
As of October 23, 2026, WGS stock price declined to $56.15 with 2,411,178 million shares trading.
WGS has a beta of 0.63, meaning it tends to be less sensitive to market movements. WGS has a correlation of 0.01 to the broad based SPY ETF.
WGS has a market cap of $1.67 billion. This is considered a Small Cap stock.
Last quarter Genedx Holdings Corp. - Class A reported $114 million in Revenue and $.01 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.20.
In the last 3 years, WGS traded as high as $170.87 and as low as $1.16.
The top ETF exchange traded funds that WGS belongs to (by Net Assets): ARKK, ARKE, VTI, ARKG, IWM.
WGS has underperformed the market in the last year with a price return of -53.6% while the SPY ETF gained +14.9%. WGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.3% and -17.1%, respectively, while the SPY returned +1.9% and -1.8%, respectively.
WGS support price is $63.77 and resistance is $70.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WGS shares will trade within this expected range on the day.
